Clinical Trial Update: Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

View source ↗

Summary

This document reports a clinical trial update for INTeRCePT 2.0 evaluating dynamic risk profiling in patients with relapsed/refractory lymphoid malignancies tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Neoplasms
• Lymphoma

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: University of Zurich | Conditions: Lymphoma, Lymphoid Hematological Malignancies | Status: RECRUITING